ACCELERA RECOGNIZED FOR DEVELOPMENT OF FEXINIDAZOLE.
The development of fexinidazole for the treatment of African
trypanosomiasis, commonly known as "sleeping sickness", by
DNDi (Drugs for Neglected Diseases initiative), along with . . .
SUBJECTS ENROLLED IN PRESEPT COLORECTAL CANCER SCREENING.
Epigenomics AG (Frankfurt:ECX), a molecular diagnostics company
focusing on the development and commercialization of products for cancer
detection based on DNA methylation, has announced the . . .
BIOTAGE LAUNCHES NEW 24 WELL PYROSEQUENCING SYSTEM.
Pyrosequencing AB, a subsidiary of Biotage AB, Uppsala, Sweden, has
announced the launch of PyroMark(TM)Q24 the latest in the range of
Pyrosequencing(R) Systems. This new high-performance platform . . .
VICAL LICENCEE ANGES MG FILES NDA IN JAPAN FOR
COLLATEGENE.
Vical Incorporated (NASDAQ:VICL), San Diego, Calif., has announced
the company's licensee, AnGes MG, Inc., reported submission on of a
New Drug Application (NDA) to the Japanese Ministry of Health, . . .
PAREXEL EXPANDS RELATIONSHIP WITH SYNCHRON IN INDIA.
PAREXEL International Corporation (NASDAQ:PRXL) has announced that
it has expanded its minority interest ownership in the clinical
pharmacology business of Synchron Research in Ahmedabad, India. . . .
NVENTA UNVEILS POSITIVE IMMUNOLOGICAL DATA FROM HSPE7 PHASE 1
TRIAL.
Nventa Biopharmaceuticals Corporation (TSX:NVN), San Diego. Calif.,
has announced interim immunological data from the first two cohorts of
its ongoing Phase 1 clinical trial of its lead product . . .
ABIOMED REPORTS ON EUROPEAN GROWTH STRATEGY.
Abiomed, Inc. (NASDAQ: ABMD), Danvers, Mass., has announced an
update on its European strategy to drive growth by establishing recovery
as the goal for patients experiencing acute cardiac events.
. . .
CELL THERAPEUTICS ACQUIRES ZEVLIN FROM BIOGEN IDEC.
Cell Therapeutics, Inc. (CTI) (Nasdaq, MTAX: CTIC), Seattle, has
announced that it has completed its acquisition of Zevalin(R)
(ibritumomab tiuxetan) from Biogen Idec, giving CTI sole . . .
HEMISPHERX'S CFS CLINICAL PROGRAMS REVIEWED IN
EUROPE.
Hemispherx Biopharma, Inc. (AMEX:HEB), Philadelphia, has reported
that the National Horizon Scanning Centre of the Department of Public
Health and Epidemiology at the University of Birmingham, . . .
PROGEN REPORTS ON PHASE 3 OF PI-88 FOR LIVER CANCER.
Progen Pharmaceuticals Limited (NASDAQ:PGLA), Brisbane, Australia,
has provided an update on clinical trial enrollment associated with its
phase 3 hepatocellular carcinoma (HCC, primary liver . . .
HEALTH CANADA ACCEPTS SANTHERA'S NDS FOR SNT-MC17.
Santhera Pharmaceuticals (SWX:SANN), a Swiss specialty
pharmaceutical company focused on neuromuscular diseases, announces
today that Health Canada has validated the company's filing of a
New Drug . . .
FOVEA/GENZYME SIGN OPHTHALMOLOGY RESEARCH PACT.
FOVEA Pharmaceuticals SA., Paris, has entered into a Collaborative
Research Agreement with GENZYME Corporation (Nasdaq: GENZ ). The
alliance is anchored around Fovea's proprietary high . . .
OASMIA PHARMACEUTICAL SIGNS LICENSING PACT WITH ORION.
Oasmia Pharmaceutical, Sweden and Orion Corporation, Finland, have
entered a license and distribution agreement for marketing and sales of
the human cancer drug Paclical(R) (micellar paclitaxel) in . . .
MARKETING APPLICATION FOR VORINOSTAT FILED IN EUROPE.
Merck & Co., Inc., Whitehouse Station, NJ, which operates in
many countries as Merck Sharp & Dohme or MSD, has announced that the
company has filed a marketing authorization application with . . .
QRXPHARMA BEGINS PHASE III CLINICAL TRIAL FOR PAIN
THERAPY.
QRxPharma (ASX: QRX), Sydney, Australia, has announced that a
number of patients have been treated in the first of several clinical
studies to be conducted as part of the Phase III development . . .
SURVIVAL ANALYSIS FROM SATRAPLATIN TRIAL DISAPPOINTING.
Martinsried/Munich (Germany), Princeton, N.J. and Boulder, Colo.,
October 30, 2007 - GPC Biotech AG (Frankfurt Stock Exchange: GPC; TecDAX
index; NASDAQ: GPCB) and Pharmion Corporation (NASDAQ: . . .
SNT-MC17 PHASE IIA FOR MUSCULAR DYSTROPHY ENCOURAGING.(Clinical
report)
Santhera Pharmaceuticals (SWX:SANN), a Swiss specialty
pharmaceutical company focused on neuromuscular diseases, announces
today positive, first results from a 12 month Phase IIa clinical . . .
BIOLINERX REPORTS POSITIVE RESULTS FROM BL-1020 TRIAL.(Clinical
report)
BioLineRx Ltd. (TASE:BLRX), Jerusalem, Israel, has announced
positive interim results from an ongoing Phase 2 trial of BL- 1020, a
GABA enhanced antipsychotic. The study is an open- label, . . .
UCB INITIATES PHASE III RIKRLTS TRIAL FOR EPILEPSY.
Phase III clinical trials of UCB's antiepileptic drug (AED) in
development, brivaracetam, are underway, as adjunctive therapy in
patients with refractory partial-onset epilepsy. Rikelta(TM) is . . .
OREXO'S RAPINYL NEARING REGULATORY DECISION IN
EUROPE.
Orexo's European licensing partner ProStrakan Group plc, for
the cancer breakthrough pain product Rapinyl on the European market, has
announced that Rapinyl will be referred for review by the . . .
|
|